Big Pharma Industry Shrinks While Biotech Booms
Big pharma employment dropped by 3% between 2003 and 2013, according to a new jobs report published by EP Vantage.
A new jobs report published by EP Vantage revealed that big pharma employment dropped by 3% between 2003 and 2013, relieving fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls.
The new report shows that when it comes to pharmaceutical industry jobs, big biotech and specialty drugmakers are growing in significance, more than offsetting the loss of jobs in big pharma.
Headcount more than doubled over the last decade at companies with market capitalizations of more than $30 billion, but who are not traditionally considered big pharma. Some of those gains were the result of acquisitions, such as Valeant, but groups like Novo Nordisk, Gilead Sciences, and Regeneron have seen their staff double, triple, or even quadruple based primarily on organic growth, the report finds.
“Large drug makers like Gilead are now not only outperforming big pharma, but are outhiring it,” said Lisa Urquhart, EP Vantage editor. “With the focus still on cost-cutting in big pharma, if you want a long-term career in the industry you might be better off with a smaller player.”
The report also found: Novartis is the biggest employer in the pharma sector, with a workforce of more than 135,000 people; Bristol-Myers Squibb and Pfizer topped the industry in terms of shrinking headcount, each firing 36% of their employees; and the biggest hirer of 2013 in percentage terms was Pharmacyclics, which more than doubled its headcount to 484 to support the launch of cancer drug Imbruvica.
Source: EP Vantage
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
